Wilate

Von Willebrand Disease

Wilate is used in adults and children with von Willebrand disease (VWD) for the following purposes:

• Treatment of spontaneous or trauma-induced bleeding episodes.
• Prevention of excessive bleeding during and after surgery.

It is typically prescribed when desmopressin is ineffective or cannot be used. It is used for various types of VWD, including types 1, 2, and 3.

Hemophilia A

Wilate is also indicated for use in adults and children with hemophilia A for:

• Treatment and control of bleeding episodes.
• Management of bleeding during and after surgical procedures.

This medication contains a combination of von Willebrand factor and coagulation factor VIII, which are proteins naturally found in human plasma that are necessary for blood to clot. It is not intended for the treatment of hemophilia B.

Mechanism of Action

Wilate is a concentrate made from human plasma that contains two important blood-clotting proteins: von Willebrand Factor (VWF) and Coagulation Factor VIII. These proteins work together to help the blood form clots and stop bleeding.

The Role of von Willebrand Factor

In a healthy body, von Willebrand Factor performs two primary functions:

• Platelet Adhesion: It acts like a bridge, helping tiny blood cells called platelets stick to the site of a blood vessel injury.
• Protein Protection: It binds to Factor VIII, protecting it from being broken down prematurely in the bloodstream.

For people with von Willebrand disease, Wilate replaces the missing or poorly functioning VWF, allowing platelets to stick to injured areas and stabilize the clotting process.

The Role of Factor VIII

Factor VIII is a protein that triggers a chain reaction in the blood to form a firm clot. In people with Hemophilia A, this protein is missing or not working correctly. Wilate provides the necessary Factor VIII to complete the clotting process and prevent or stop bleeding episodes.

Common Side Effects

Many people using Wilate experience mild side effects. These may include:

• Itching or rash
• Headache
• Dizziness
• Back pain
• Nausea
• Pain, swelling, or redness at the injection site
• Fever

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention. These include:

• Allergic reactions: Symptoms may include hives, chest tightness, wheezing, or swelling of the face, lips, and tongue.
• Blood clots: There is a risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, especially in patients with certain risk factors.
• Inhibitors: The body may develop neutralizing antibodies (inhibitors) that prevent the medication from working correctly.
• Infection risk: Because this product is made from human plasma, there is a remote risk of transmitting infectious agents, such as viruses, despite screening and manufacturing processes.

Hypersensitivity Reactions

Allergic-type hypersensitivity reactions may occur during treatment. Signs of a reaction include hives, itching, chest tightness, wheezing, low blood pressure, and anaphylaxis. If these symptoms occur, treatment should be discontinued immediately and emergency medical care sought.

Thromboembolic Risks

There is a risk of blood clots (thromboembolism) associated with the use of von Willebrand factor and blood clotting factor VIII products. This risk is higher in patients with known risk factors for blood clots, such as older age, recent surgery, or a history of thrombosis. Monitoring of plasma levels is recommended to avoid excessive levels of factor VIII, which can increase the risk of clotting events.

Neutralizing Antibodies

Patients may develop neutralizing antibodies, known as inhibitors, to von Willebrand factor or factor VIII. If the treatment does not achieve the expected blood levels or if bleeding is not controlled with the usual dose, a medical professional may perform tests to check for the presence of these inhibitors.

Infectious Agents

Wilate is made from human plasma. Products made from human blood may carry a risk of transmitting infectious agents, such as viruses (including hepatitis and HIV) and the agent that causes Creutzfeldt-Jakob disease (CJD). This risk is minimized by screening plasma donors and using manufacturing processes designed to inactivate or remove certain viruses.

Monitoring and Blood Group Considerations

Patients with blood groups A, B, or AB who receive large or frequent doses should be monitored for signs of intravascular hemolysis (the breakdown of red blood cells). Healthcare providers may monitor hematocrit levels and perform specific blood tests if this condition is suspected.

Pregnancy

Animal reproduction studies have not been conducted with Wilate. It is currently unknown whether this medication can cause harm to an unborn baby or affect a person's ability to conceive. Because of the lack of clinical data, Wilate should be administered to a pregnant woman only if the potential benefits outweigh the risks and it is clearly needed.

Breastfeeding

It is not known whether the components of Wilate pass into human breast milk. Because many drugs are excreted in human milk, caution should be exercised when this medication is administered to someone who is nursing. Healthcare providers typically evaluate the importance of the drug to the mother when deciding whether to continue or discontinue breastfeeding during treatment.

Consult Your Healthcare Provider

If you are pregnant, planning to become pregnant, or are breastfeeding, discuss your treatment options with your doctor. They can help evaluate the risks and benefits of using Wilate based on your specific medical needs and the severity of your condition.

Dosage Form

Wilate is supplied as a lyophilized (freeze-dried) powder for solution. It is intended for intravenous injection only after it has been reconstituted with the provided sterile water.

Kit Components

This medication is typically distributed in a kit containing the materials needed for a single administration. The kit generally includes:

• A vial containing the medication in powder form.
• A vial of sterile water for injection, which acts as the diluent.
• A needleless transfer device used to mix the liquid into the powder vial.

The powder must be completely dissolved before use. The resulting solution should be clear or slightly pearlescent; it should not be used if it is cloudy or contains visible particles.

FDA Approval and Indications

Wilate was approved by the U.S. Food and Drug Administration (FDA) as a freeze-dried concentrate of human von Willebrand factor (VWF) and coagulation factor VIII (FVIII). It is authorized for use in both pediatric and adult patients for the following indications:

• von Willebrand Disease (VWD): For the on-demand treatment and control of bleeding episodes, and for the perioperative management of bleeding in patients with VWD.
• Hemophilia A: For the on-demand treatment and control of bleeding episodes, and for the perioperative management of bleeding in patients with hemophilia A.

Regulatory Safety Information

There are no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required for Wilate. As a product derived from human plasma, it carries standard regulatory warnings regarding the potential risk of transmitting infectious agents, such as viruses and the variant Creutzfeldt-Jakob disease (vCJD) agent. This risk is mitigated through donor screening and viral inactivation and removal steps during the manufacturing process.

Regulatory labeling also includes warnings regarding hypersensitivity reactions and the potential development of neutralizing antibodies (inhibitors) against VWF or FVIII. Patients and providers are advised to monitor for these conditions during treatment.

Factors Influencing Cost

Wilate is a specialty biologic medication, and its price is typically based on the number of International Units (IU) prescribed. Several factors can affect the total cost of treatment:

• Dosage and Weight: Because dosing is often based on body weight and the severity of the clotting factor deficiency, larger doses will increase the price per treatment.
• Treatment Frequency: Patients using Wilate for routine prophylaxis (prevention of bleeding) will generally have higher overall costs than those using it only on-demand for acute bleeding episodes.
• Vial Strength: Wilate is supplied in kits containing different strengths, such as 500 IU or 1000 IU vials, which are priced accordingly.

Insurance and Financial Assistance

Most health insurance plans, including Medicare and Medicaid, provide coverage for Wilate when it is medically necessary for von Willebrand disease or Hemophilia A. However, patients may still be responsible for out-of-pocket costs, such as deductibles, co-payments, or co-insurance.

Because it is a specialty drug, Wilate is usually obtained through specialty pharmacies rather than standard retail locations. The manufacturer may offer patient assistance programs or co-pay savings cards to help eligible individuals manage their out-of-pocket expenses.